Program Chair

David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
St. Petersburg, FL

PROGRAM OVERVIEW

This enduring educational program aims to increase clinicians’ awareness of gaps and burdens associated with treatment of diabetic macular edema (DME) that can contribute to poorer vision outcomes. Along with didactic presentation, this activity will include small group case-study discussions to provide retina specialists and comprehensive ophthalmologists will acquire knowledge and tactics to address these barriers through individualized approaches to treatment, such as dosing strategies and use of next-generation anti-VEGF therapy. Featuring a panel discussion to enhance the practical integration of addressing treatment burden.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.

LEARNING OBJECTIVES

• Evaluate adherence barriers in DME treatment, including injection frequency and patient factors
• Analyze the duration of effectiveness in established and emerging therapies for DME
• Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
• Personalize treatment selection and dosing strategies to optimize care for DME patients

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

David Eichenbaum, MD discloses the following:

• Speakers’ Bureau: Alimera, Allergan, Apellis, Astellas, Bayer, Genentech, Regeneron Pharmaceuticals, Inc.
• Consultant: 4DMT, Alimera, Allergan, Amaros, Annexon, Apellis, Astellas, Bausch & Lomb, Bayer, Coherus, CorEvitas/Vestrum, Complement Therapeutics, Crinetics, EyePoint, Genentech, Harrow, Kodiak, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Outlook, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, ReVive, RetinAI, Roche, Samsara, Stealth, and Tilak
• Investigator: 4DMT, Aerie/Alcon, Alexion, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, Priovant, RecensMedica, Regeneron Pharmaceuticals, Inc., Regenxbio, Roche, Stealth, and Unity
• Equity/Stockholder/Options: Amaros, Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina
• Founder: Network Eye

All relevant financial relationships have been mitigated.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

• Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
• Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
• Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
• Brianna Hefele, PA-C has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Kristen Marks, Program Coordinator of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

RELEASED DATE: December 01, 2024
EXPIRATION DATE: December 01, 2025

Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.